A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca Plc (Nasdaq: AZN)’s $1 billion deal to acquire closely-held Amolyt Pharma illustrates, the likelihood is there’s much more to come.
To read the entire story, you must be logged in.
Please log in now or register with us.
